Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2025.116198 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Wei Guo und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, Beijing Nova Program, National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant camrelizumab plus apatinib has shown a promising major pathological response (primary endpoint) and pathological complete response (a secondary endpoint) in patients with resectable stage IIA-IIIB non-small-cell lung cancer (NSCLC) in a previous single-arm phase 2 trial. Here, we present the 3-year survival outcomes and potential prognostic factors with extended follow-up. METHODS: This single-arm phase 2 study enrolled patients with resectable stage IIA-IIIB NSCLC (stage IIIB, T3N2 only, according to the eighth edition of the American Joint Commission on Cancer TNM staging classification). Patients received three cycles of neoadjuvant camrelizumab (200 mg, intravenously, q2w) and apatinib (250 mg, orally, qd, for 5 days followed by 2 days off) followed by surgery. At 4-8 weeks after surgery, patients received either adjuvant camrelizumab monotherapy for up to 12 cycles or other strategies at the investigator's discretion. RESULTS: With the median follow-up of 42.6 months, the 3-year event-free survival (EFS), disease-free survival and overall survival were 58.9 % (95 % CI 46.9-69.1), 61.5 % (95 % CI 48.6-72.1), and 92.3 % (95 % CI 83.6-96.5), respectively. Among the pathological responses, residual viable tumors of ≤ 20 % were more strongly associated with improved EFS (HR 0.30, 95 % CI 0.13-0.72). Additionally, metabolic response on PET/CT after neoadjuvant treatment and ctDNA clearance during the perioperative period were significantly associated with improved EFS (HR 0.23 [95 % CI 0.08-0.62] and HR 0.23 [95 % CI 0.09-0.59], respectively). CONCLUSIONS: Neoadjuvant camrelizumab plus apatinib provides a potential sustained benefit for patients with resectable stage IIA-IIIB NSCLC. Metabolic response on PET/CT and perioperative ctDNA clearance might be potential biomarkers for predicting survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China; Key Laborator…
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- GCP center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- PET-CT center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, PR China.
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- Beijing Nova Program
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Jiangsu Hengrui Medicine
Zitieren
APA
Guo, W., Zhao, L., Chen, X., Wang, S., Tao, X., Li, L., Sun, Q., Gao, Y., Mao, Y., Shao, K., Lv, F., Zhang, L., Lei, W., Wang, D., Li, Z., Su, K., Wang, B., Feng, F., Chen, X., …, & Gao, S. (2026). Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116198
Vancouver
Guo W, Zhao L, Chen X, Wang S, Tao X, Li L, et al. Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116198
BibTeX
@article{Guo2026,
author = {Guo, Wei and Zhao, Liang and Chen, Xiaowei and Wang, Shuhang and Tao, Xiuli and Li, Lin and Sun, Qianqian and Gao, Yushun and Mao, Yousheng and Shao, Kang and Lv, Fang and Zhang, Liangze and Lei, Wendong and Wang, Dali and Li, Zhishan and Su, Kai and Wang, Bing and Feng, Feiyue and Chen, Xinjie and Wu, Ning and Ying, Jianming and Xue, Qi and Li, Ning and Zhao, Jun and Tan, Fengwei and Gao, Shugeng},
title = {Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2025.116198}
}
EUVIMED